

External Quality Assessment Program for

## Next Generation Sequencing (NGS) for somatic tumours

Labquality, an independent provider of External Quality Assessment (EQA) schemes with over 50 years of experience, is introducing a new product line for Next Generation Sequencing (NGS) for somatic tumours. We are inviting a limited number of laboratories to participate free of charge in a pilot study for this new scheme. The scheme is suitable for all NGS methods.

This pilot study includes one DNA sample, to be analysed as a routine patient sample according to the established workflow and panel selection of the laboratory. Using this sample, participants may report 1-3 cases in the areas of breast cancer, lung cancer, or colorectal cancer, following the specified gene list. Results will be submitted via the electronic platform LabScala and assessed by the Scheme Expert against the expected findings.

### 6810 NGS for somatic tumours

**Samples:** 1 DNA sample as a scroll from a FFPE block

Markers:

Case1: ALK, BRAF, EGFR, KRAS and fusions: ROS1, ALK, RET and CNVt:ME

Case 2: AKT1, BRCA1, BRCA2, ERBB2, PIK3CA, TP53 and CNVt:ERBB2

Case 3: KRAS, NRAS, TP53 and CNVt ERBB2

**Distribution:** Spring 2026

**Registration:** Please register by [this link](#) or by scanning this QR code  
no later than 31 January 2026



### For more information

Labquality's customer service [info@labquality.com](mailto:info@labquality.com) or

**Pia Eloranta**  
EQA Coordinator  
[pia.eloranta@labquality.com](mailto:pia.eloranta@labquality.com)  
+358 50 3627 942

**Heidi Berghäll**  
EQA Solution manager, R&D  
[heidi.berghall@labquality.com](mailto:heidi.berghall@labquality.com)  
+358 50 356 0503